Fate Therapeutics Inc (FATE)

[jondoeuk]

A new study challenges the "transient depletion" paradigm https://academic.oup.com/jmcb/advance-article/doi/10.1093/jmcb/mjag002/8469379

This could end the transient, re-dosable (m)RNA approach for a number of companies. This would leave integrating CARs. Non-viral delivery, with site-specific integration would likely win over those working on viral delivery (+/- non site-specific integration).